SCHEMBL5136891

SCHEMBL5136891

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1cc(F)ccc1F)CC1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
P2RX7 Q99572 1/20 0.37
CCR4 P51679 3/20 0.36
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36
HDAC1 Q13547 1/20 0.36
TSHR P16473 4/20 0.35
CRHR1 P34998 4/20 0.34
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 3/20 0.34
CYP3A4 P08684 3/20 0.34
HSD17B10 Q99714 3/20 0.34
HPGD P15428 2/20 0.34
HTR2C P28335 3/20 0.34
DRD1 P21728 2/20 0.34
DRD4 P21917 2/20 0.34
DRD5 P21918 2/20 0.34
DRD3 P35462 2/20 0.34
HTR2A P28223 1/20 0.33
SLC6A4 P31645 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135938 0.94 C5AR1 (0.41) C5AR1P2RX7CCR4BCHEACHE
SCHEMBL5136106 0.92 C5AR1 (0.41) C5AR1P2RX7CCR4BCHEACHE
SCHEMBL651851 0.91 C5AR1 (0.40) C5AR1P2RX7CCR4BCHEACHE
SCHEMBL649769 0.91 C5AR1 (0.40) C5AR1CCR4BCHEACHEHDAC1
SCHEMBL5137114 0.89 C5AR1 (0.43) C5AR1P2RX7BCHEHDAC1TSHR
SCHEMBL650740 0.88 C5AR1 (0.39) C5AR1P2RX7CCR4BCHEACHE
SCHEMBL5135166 0.88 C5AR1 (0.45) C5AR1P2RX7CCR4BCHEACHE
SCHEMBL650474 0.88 C5AR1 (0.42) C5AR1P2RX7CCR4BCHEACHE
SCHEMBL651501 0.87 C5AR1 (0.44) C5AR1HDAC1TSHRCRHR1KDM4E
SCHEMBL5137556 0.87 C5AR1 (0.40) C5AR1CCR4BCHEACHEHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed